Drug intelligence / Profile preview

SimeCOS

Development stage: Unknown
Lead developer: Genís
Modality: Small Molecules

Overview

SimeCOS is a therapeutic chitooligosaccharide (ChOS) developed by Genís, an Icelandic biotechnology company. It is designed to target and modulate YKL-40 (also known as Chitinase-3-like protein 1) and other chitinase-like proteins (CLPs). YKL-40 is a biomarker and mediator of chronic inflammation, tissue remodeling, and fibrosis, and is elevated in various inflammatory and malignant conditions. By inhibiting or modulating these proteins, SimeCOS aims to treat a broad range of disorders, including asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, cardiovascular disease, and certain cancers. The drug is currently in the preclinical or early research stage, although a clinical study was conducted in 2017 at Herlev Hospital to evaluate its potential.

Other names: Chitooligosaccharides

Targets

CHI3L1 (Chitinase-3-like protein 1)

Beyond the preview

Go deeper on SimeCOS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SimeCOS.

Explore the full profile